The Alopecia Areata Severity And Morbidity Index (ASAMI) Study

February 2024 in “ JAMA Dermatology ”

Anthony Moussa, Michaela Bennett, Dmitri Wall, Nekma Meah, Katherine York, Laita Bokhari, Leila Asfour, Huw Rees, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, F. Buket Basmanav, Wilma F. Bergfeld, Regina C. Betz, Bevin Bhoyrul, Ulrike Blume‐Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalía, George Cotsarelis, Brittany G. Craiglow, Rachita Dhurat, Jeff Donovan, Andrei G. Doroshkevich, Samantha Eisman, Paul Farrant, Juan Ferrando, Aida Gadzhigoroeva, Jack Green, Ramón Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Victoria Jolliffe, Spartak Kaiumov, Brett King, Joyce Lee, Won‐Soo Lee, Jane Li, Nino Lortkipanidze, Amy McMichael, Natasha Atanaskova Mesinkovska, Andrew G. Messenger, Paradi Mirmirani, Elise A. Olsen, Seth J. Orlow, Yuliya Ovcharenko, Bianca Maria Piraccini, Rodrigo Pirmez, Adriana Rakowska, Pascal Reygagne, Lidia Rudnicka, David Saceda Corralo, Maryanne M. Senna, Jerry Shapiro, Pooja Sharma, Tatiana Siliuk, Michela Starace, Poonkiat Suchonwanit, Anita Takwale, Antonellá Tosti, Sergio Vañó‐Galván, Willem I. Visser, Annika Vogt, Martin Wade, Leona Yip, Cheng Zhou, Rodney Sinclair, Rodney Sinclair

alopecia areata scalp hair loss facial involvement nail involvement Alopecia Areata Severity and Morbidity Index AA ASAMI

Studysummary This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on escholarship.org →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Signposts to the Promised Land in Alopecia Areata

September 2022 in “Journal of Investigative Dermatology”

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

research Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

56 citations , August 2020 in “American Journal of Clinical Dermatology”

This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.

SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss

The Alopecia Areata Severity And Morbidity Index (ASAMI) Study

Research cited in this study

research Signposts to the Promised Land in Alopecia Areata

research Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

research SALT II: A New Take on the Severity of Alopecia Tool for Determining Percentage Scalp Hair Loss

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss